Kesheng Meng - Search Results

Year	Number of Results
1997	1
2002	2
2003	6
2004	4
2005	3
2006	4
2007	7
2008	7
2009	4
2010	3
2011	6
2012	4
2013	1
2014	4
2015	2
2016	1
2017	2
2018	5
2019	4
2020	5
2024	1

1

Advances in the Development of Phosphodiesterase-4 Inhibitors.

Peng T, Qi B, He J, Ke H, Shi J. Peng T, et al. Among authors: ke h. J Med Chem. 2020 Oct 8;63(19):10594-10617. doi: 10.1021/acs.jmedchem.9b02170. Epub 2020 Jun 10. J Med Chem. 2020. PMID: 32255344 Review.

2

Advances in targeting cyclic nucleotide phosphodiesterases.

Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Maurice DH, et al. Among authors: ke h. Nat Rev Drug Discov. 2014 Apr;13(4):290-314. doi: 10.1038/nrd4228. Nat Rev Drug Discov. 2014. PMID: 24687066 Free PMC article. Review.

3

Structures of calcineurin and its complexes with immunophilins-immunosuppressants.

Ke H, Huai Q. Ke H, et al. Biochem Biophys Res Commun. 2003 Nov 28;311(4):1095-102. doi: 10.1016/s0006-291x(03)01537-7. Biochem Biophys Res Commun. 2003. PMID: 14623295 Review.

4

Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases.

Xiang Y, Naik S, Zhao L, Shi J, Ke H. Xiang Y, et al. Among authors: ke h. Med Res Rev. 2024 Jan 27. doi: 10.1002/med.22017. Online ahead of print. Med Res Rev. 2024. PMID: 38279990 Review.

5

Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.

Shakur Y, de Koning HP, Ke H, Kambayashi J, Seebeck T. Shakur Y, et al. Among authors: ke h. Handb Exp Pharmacol. 2011;(204):487-510. doi: 10.1007/978-3-642-17969-3_20. Handb Exp Pharmacol. 2011. PMID: 21695653 Review.

6

Crystal structures of cyclophilin and its partners.

Ke H, Huai Q. Ke H, et al. Front Biosci. 2004 Sep 1;9:2285-96. doi: 10.2741/1396. Front Biosci. 2004. PMID: 15353287 Review.

7

Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds.

Francis SH, Sekhar KR, Ke H, Corbin JD. Francis SH, et al. Among authors: ke h. Handb Exp Pharmacol. 2011;(200):93-133. doi: 10.1007/978-3-642-13443-2_4. Handb Exp Pharmacol. 2011. PMID: 20859794 Review.

8

Structural insight into the substrate specificity of phosphodiesterases.

Ke H, Wang H, Ye M. Ke H, et al. Handb Exp Pharmacol. 2011;(204):121-34. doi: 10.1007/978-3-642-17969-3_4. Handb Exp Pharmacol. 2011. PMID: 21695637 Review.

9

Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies.

Zhu C, Dukhovlinova E, Council O, Ping L, Faison EM, Prabhu SS, Potter EL, Upton SL, Yin G, Fay JM, Kincer LP, Spielvogel E, Campbell SL, Benhabbour SR, Ke H, Swanstrom R, Dokholyan NV. Zhu C, et al. Among authors: ke h. Nat Commun. 2019 Feb 27;10(1):948. doi: 10.1038/s41467-019-08876-w. Nat Commun. 2019. PMID: 30814513 Free PMC article.

10

Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity.

Ke H, Wang H. Ke H, et al. Curr Top Med Chem. 2007;7(4):391-403. doi: 10.2174/156802607779941242. Curr Top Med Chem. 2007. PMID: 17305581 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

70 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year